答复"恩替卡韦治疗停止后 HBsAg 消失的预测"

IF 26.8 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen
{"title":"答复\"恩替卡韦治疗停止后 HBsAg 消失的预测\"","authors":"Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen","doi":"10.1016/j.jhep.2024.10.041","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>AUTHOR CONTRIBUTIONS</h2>RWH Hui was involved in manuscript design and drafting of manuscript. LY Mak was involved in critical revision of manuscript. MF Yuen was involved in critical revision of manuscript and overall study supervision. The authors declare that they have participated in the preparation of the manuscript and have seen and approved the final version.</section></section><section><section><h2>DISCLOSURES/ CONFLICT OF INTEREST STATEMENT</h2>MF Yuen is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation and Sysmex Corporation. The remaining authors have no conflict of interests.</section></section><section><section><h2>DATA AVAILABILITY STATEMENT</h2>The data from this study is available from the corresponding author upon reasonable request.</section></section><section><section><h2>Funding</h2>Innovative Research Fund of the State Key Laboratory of Liver Research, The University of Hong Kong (ref. no.: SKLLR/IRF/2018/07) and the S. K. Yee Medical Foundation Grant (ref. no.: 2141213). The funders had no involvement in study design, data collection/ analysis/ interpretation, writing of the manuscript or decision to submit the article for publication.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"61 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reply to: “Prediction of HBsAg loss after cessation of entecavir therapy”\",\"authors\":\"Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen\",\"doi\":\"10.1016/j.jhep.2024.10.041\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h2>Section snippets</h2><section><section><h2>AUTHOR CONTRIBUTIONS</h2>RWH Hui was involved in manuscript design and drafting of manuscript. LY Mak was involved in critical revision of manuscript. MF Yuen was involved in critical revision of manuscript and overall study supervision. The authors declare that they have participated in the preparation of the manuscript and have seen and approved the final version.</section></section><section><section><h2>DISCLOSURES/ CONFLICT OF INTEREST STATEMENT</h2>MF Yuen is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation and Sysmex Corporation. The remaining authors have no conflict of interests.</section></section><section><section><h2>DATA AVAILABILITY STATEMENT</h2>The data from this study is available from the corresponding author upon reasonable request.</section></section><section><section><h2>Funding</h2>Innovative Research Fund of the State Key Laboratory of Liver Research, The University of Hong Kong (ref. no.: SKLLR/IRF/2018/07) and the S. K. Yee Medical Foundation Grant (ref. no.: 2141213). The funders had no involvement in study design, data collection/ analysis/ interpretation, writing of the manuscript or decision to submit the article for publication.</section></section>\",\"PeriodicalId\":15888,\"journal\":{\"name\":\"Journal of Hepatology\",\"volume\":\"61 1\",\"pages\":\"\"},\"PeriodicalIF\":26.8000,\"publicationDate\":\"2024-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jhep.2024.10.041\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2024.10.041","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

章节片段作者贡献RWH Hui参与了手稿的设计和起草。LY Mak 参与了稿件的重要修改。MF Yuen 参与了稿件的关键修改和整个研究的监督。作者声明:他们参与了手稿的准备工作,并审阅和批准了最终版本。声明/利益冲突声明MF Yuen 是艾伯维、Arbutus Biopharma、Assembly Biosciences、Bristol Myer Squibb、Dicerna Pharmaceuticals、葛兰素史克、吉利德科学、杨森、默克夏普和多美、Clear B Therapeutics、Springbank Pharmaceuticals 的顾问委员会成员和/或接受其研究资助;并接受 Arrowhead Pharmaceuticals、Fujirebio Incorporation 和 Sysmex Corporation 的研究资助。其余作者无利益冲突。数据提供声明本研究的数据可向相应作者索取。资助者没有参与研究设计、数据收集/分析/解释、手稿撰写或决定将文章提交发表。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Reply to: “Prediction of HBsAg loss after cessation of entecavir therapy”

Section snippets

AUTHOR CONTRIBUTIONS

RWH Hui was involved in manuscript design and drafting of manuscript. LY Mak was involved in critical revision of manuscript. MF Yuen was involved in critical revision of manuscript and overall study supervision. The authors declare that they have participated in the preparation of the manuscript and have seen and approved the final version.

DISCLOSURES/ CONFLICT OF INTEREST STATEMENT

MF Yuen is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation and Sysmex Corporation. The remaining authors have no conflict of interests.

DATA AVAILABILITY STATEMENT

The data from this study is available from the corresponding author upon reasonable request.

Funding

Innovative Research Fund of the State Key Laboratory of Liver Research, The University of Hong Kong (ref. no.: SKLLR/IRF/2018/07) and the S. K. Yee Medical Foundation Grant (ref. no.: 2141213). The funders had no involvement in study design, data collection/ analysis/ interpretation, writing of the manuscript or decision to submit the article for publication.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Hepatology
Journal of Hepatology 医学-胃肠肝病学
CiteScore
46.10
自引率
4.30%
发文量
2325
审稿时长
30 days
期刊介绍: The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信